Page last updated: 2024-10-30
losartan and Abdominal Obesity
losartan has been researched along with Abdominal Obesity in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " In the present study, we examined the effects of ARB (angiotensin receptor blocker) therapy (losartan, 100 mg/day) on insulin sensitivity and endothelial function in 53 subjects with stage I hypertension, abdominal obesity and impaired fasting glucose." | 5.16 | Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. ( Abate, NI; Albu, JB; Creager, MA; Grundy, SM; Henry, RR; Mai, Y; Marks, JB; Mather, KJ; Perlstein, TS; Pool, JL; Rickels, MR, 2012) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Perlstein, TS | 1 |
| Henry, RR | 1 |
| Mather, KJ | 1 |
| Rickels, MR | 1 |
| Abate, NI | 1 |
| Grundy, SM | 1 |
| Mai, Y | 1 |
| Albu, JB | 1 |
| Marks, JB | 1 |
| Pool, JL | 1 |
| Creager, MA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose[NCT00675987] | Phase 4 | 53 participants (Actual) | Interventional | 2007-05-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in E-selectin
E-selectin is expressed on inflamed endothelial cells in response to treatment with inflammatory cytokines. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | ng/ml (Mean) |
|---|
| Placebo | -1.6 |
| Losartan | -0.6 |
Change in F2-isoprostanes
F2-isoprostanes is a marker of oxidative stress. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | ng/mg of creatinine (Mean) |
|---|
| Placebo | 0.4 |
| Losartan | 0.9 |
Change in hsCRP (High-sensitivity C-reactive Protein)
hsCRP (high-sensitivity C-reactive protein) is a marker of inflammation (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | percentage change (Mean) |
|---|
| Placebo | -10 |
| Losartan | -34 |
Change in MCP-1 (Monocyte Chemoattractant Protein-1)
MCP-1 is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | pg/ml (Mean) |
|---|
| Placebo | -37 |
| Losartan | -24 |
Change in Ox-LDL (Oxidized Low-density Lipoprotein)
ox-LDL measures protein damage due to the oxidative modification of the ApoB subunit on LDL cholesterol. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | units/l (Mean) |
|---|
| Placebo | -2.0 |
| Losartan | -5.5 |
Change in Urine Albumin/Creatine
Urine was obtained to assess for the presence of microalbuminuria. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | mg/mmol (Mean) |
|---|
| Placebo | 0.4 |
| Losartan | 0.2 |
Change in VCAM-1(Vascular Cell-adhesion Molecule-1)
VCAM-1 is an immunoglobulin-like adhesion molecule expressed on activated endothelial cells. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | ng/ml (Mean) |
|---|
| Placebo | 29 |
| Losartan | -21 |
Insulin Sensitivity Utilizing Endothelial Function as Assessed by Pulse Volume Amplitude
Endothelial function assessed as the ratio of pulse volume amplitude after compared with before a reactive hyperemia stimulus, measured by peripheral (fingertip) arterial tonometry. Reported values indicate the percentage change from Baseline in the ratio of pulse volume amplitude after compared to before the reactive hyperemia stimulus. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | percentage change (Mean) |
|---|
| Placebo | 1.76 |
| Losartan | 2.11 |
Insulin Sensitivity Utilizing the Euglycemic Hyperinsulinemic Clamp
Insulin clamp derived insulin sensitivity, as insulin stimulated glucose disposal corrected for steady state insulin level. (NCT00675987)
Timeframe: baseline, 8 weeks
| Intervention | mg/kg/min (Mean) |
|---|
| Placebo | 5.3 |
| Losartan | 2.8 |
Trials
1 trial available for losartan and Abdominal Obesity